Tumor necrosis factor receptor superfamily member 19 (TNFRSF19), also known as TROY; TNFRSF19 (also known as TAJ; TROY; TRADE; TAJ-alpha) is expressed in progenitor cells of the hippocampus, thalamus, and cerebral cortex and highly expressed during embryonic development. It has been shown to interact with TRAF family members, and to activate JNK signaling pathway when overexpressed in cells. It is frequently overexpressed in colorectal cancer cell lines and primary colorectal carcinomas. TNFRSF19 is a beta-catenin target gene, in mesenchymal stem cells, and also activates NF-kappaB signaling, showing that beta-catenin regulates NF-kappaB activity via TNFRSF19. Since Wnt/beta-catenin signaling plays a crucial role in the regulation of colon tissue regeneration and the development of colon tumors, TNFRSF19 may contribute to the development of colorectal tumors. These findings define a role for death receptors DR6 and TROY in CNS-specific vascular development. TNFRSF19 has been shown to promote glioblastoma (GBM) survival signaling and therefore targeting it may increase tumor vulnerability and improve therapeutic response in glioblastoma. It may play an important role in myelin-associated inhibitory factors (MAIFs)-induced inhibition of neurite outgrowth in the postnatal central nervous system (CNS) or on axon regeneration following CNS injury.

                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1207117557  33 DCREQEYKDKFGSCIPCRQCDAGQELSKECGFGYGEDAQCVPCRASRFKEDRSLQKCKPCLDCSLLNRFQKGNCSTTNNA 112
Cdd:cd13418     1 DCREQEYRDKAGNCIPCRQCGPGMELSKECGFGYGEDAQCVPCRPNRFKEDWGFQKCKPCLDCALLNRFQKANCSATSNA 80

                          90       100       110
                  ....*....|....*....|....*....|....*..
gi 1207117557 113 VCGDCLPGFYRKTKLRGFQDMECIPCGDPPPPYETHC 149
Cdd:cd13418    81 VCGDCLPGFYRKTKLVGFQDMECVPCGDPPPPYEPHC 117

Tumor necrosis factor receptor superfamily member 19 (TNFRSF19), also known as TROY; TNFRSF19 (also known as TAJ; TROY; TRADE; TAJ-alpha) is expressed in progenitor cells of the hippocampus, thalamus, and cerebral cortex and highly expressed during embryonic development. It has been shown to interact with TRAF family members, and to activate JNK signaling pathway when overexpressed in cells. It is frequently overexpressed in colorectal cancer cell lines and primary colorectal carcinomas. TNFRSF19 is a beta-catenin target gene, in mesenchymal stem cells, and also activates NF-kappaB signaling, showing that beta-catenin regulates NF-kappaB activity via TNFRSF19. Since Wnt/beta-catenin signaling plays a crucial role in the regulation of colon tissue regeneration and the development of colon tumors, TNFRSF19 may contribute to the development of colorectal tumors. These findings define a role for death receptors DR6 and TROY in CNS-specific vascular development. TNFRSF19 has been shown to promote glioblastoma (GBM) survival signaling and therefore targeting it may increase tumor vulnerability and improve therapeutic response in glioblastoma. It may play an important role in myelin-associated inhibitory factors (MAIFs)-induced inhibition of neurite outgrowth in the postnatal central nervous system (CNS) or on axon regeneration following CNS injury.

                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1207117557  33 DCREQEYKDKFGSCIPCRQCDAGQELSKECGFGYGEDAQCVPCRASRFKEDRSLQKCKPCLDCSLLNRFQKGNCSTTNNA 112
Cdd:cd13418     1 DCREQEYRDKAGNCIPCRQCGPGMELSKECGFGYGEDAQCVPCRPNRFKEDWGFQKCKPCLDCALLNRFQKANCSATSNA 80

                          90       100       110
                  ....*....|....*....|....*....|....*..
gi 1207117557 113 VCGDCLPGFYRKTKLRGFQDMECIPCGDPPPPYETHC 149
Cdd:cd13418    81 VCGDCLPGFYRKTKLVGFQDMECVPCGDPPPPYEPHC 117

Tumor necrosis factor receptor superfamily member 19 (TNFRSF19), also known as TROY; TNFRSF19 (also known as TAJ; TROY; TRADE; TAJ-alpha) is expressed in progenitor cells of the hippocampus, thalamus, and cerebral cortex and highly expressed during embryonic development. It has been shown to interact with TRAF family members, and to activate JNK signaling pathway when overexpressed in cells. It is frequently overexpressed in colorectal cancer cell lines and primary colorectal carcinomas. TNFRSF19 is a beta-catenin target gene, in mesenchymal stem cells, and also activates NF-kappaB signaling, showing that beta-catenin regulates NF-kappaB activity via TNFRSF19. Since Wnt/beta-catenin signaling plays a crucial role in the regulation of colon tissue regeneration and the development of colon tumors, TNFRSF19 may contribute to the development of colorectal tumors. These findings define a role for death receptors DR6 and TROY in CNS-specific vascular development. TNFRSF19 has been shown to promote glioblastoma (GBM) survival signaling and therefore targeting it may increase tumor vulnerability and improve therapeutic response in glioblastoma. It may play an important role in myelin-associated inhibitory factors (MAIFs)-induced inhibition of neurite outgrowth in the postnatal central nervous system (CNS) or on axon regeneration following CNS injury.

                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1207117557  33 DCREQEYKDKFGSCIPCRQCDAGQELSKECGFGYGEDAQCVPCRASRFKEDRSLQKCKPCLDCSLLNRFQKGNCSTTNNA 112
Cdd:cd13418     1 DCREQEYRDKAGNCIPCRQCGPGMELSKECGFGYGEDAQCVPCRPNRFKEDWGFQKCKPCLDCALLNRFQKANCSATSNA 80

                          90       100       110
                  ....*....|....*....|....*....|....*..
gi 1207117557 113 VCGDCLPGFYRKTKLRGFQDMECIPCGDPPPPYETHC 149
Cdd:cd13418    81 VCGDCLPGFYRKTKLVGFQDMECVPCGDPPPPYEPHC 117

tumor necrosis factor receptor superfamily member 19-like (TNFRSF19L), also known as receptor expressed in lymphoid tissues (RELT); TNFRSF19L (also known as receptor expressed in lymphoid tissues (RELT)) is especially abundant in hematologic tissues and can stimulate the proliferation of T-cells. It serves as a substrate for the closely related kinases, odd-skipped related transcription factor 1 (OSR1) and STE20/SPS1-related proline/alanine-rich kinase (SPAK); RELT binds SPAK and uses it to mediate p38 and JNK activation, rather than rely on the canonical TRAF pathways for its function. RELT is capable of stimulating T-cell proliferation in the presence of CD3 signaling, which suggests its regulatory role in immune response. It interacts with phospholipid scramblase 1 (PLSCR1), an interferon-inducible protein that mediates antiviral activity against DNA and RNA viruses; PLSCR1 is a regulator of hepatitis B virus X (HBV X) protein. RELT and PLSCR1 co-localize in intracellular regions of human embryonic kidney-293 cells, with RELT over-expression appearing to alter the localization of PLSCR1.

                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1207117557  46 CIPCRQCDAGQELSKECGFGYGEDAQCVPCRASRFKEDRSLQKCKPCLDCSLLNRFQKGNCSTTNNAVCGDCLPGFYrkt 125
Cdd:cd13419     1 CVPCLQCPPGQEPDRACGQGQGLGVLCRSCPPGTFSDSLGSEPCRPHTSCEVLKRKVATSGTATSDAVCGDCLPGFH--- 77

                          90
                  ....*....|...
gi 1207117557 126 KLRGFQDMECIPC 138
Cdd:cd13419    78 SPAAPPPSTCLPC 90

Tumor necrosis factor receptor superfamily member ectodysplasin A receptor (EDAR); Ectodysplasin A receptor (EDAR, also known as DL, ED3, ED5, ED1R, EDA3, HRM1, EDA1R, ECTD10A, ECTD10B, EDA-A1R) binds the soluble ligand ectodysplasin A and can activate the nuclear factor-kappaB, JNK, and caspase-independent cell death pathways. It is required for the development of hair, teeth, and other ectodermal derivatives. Mutations in this gene result in autosomal dominant and recessive forms of hypohidrotic ectodermal dysplasia. Patients present defects in the development of ectoderm-derived structures resulting in sparse hair, too few teeth (oligodontia), the absence or reduction in the ability to sweat as well as problems with mucous and saliva and the production and formation of pigment cells.

                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1207117557  23 LFAVMAEERRDCREQEYKDKF-GSCIPCRQCDAGQELSKECGFGY-GEDAQCVPCRASRFKEDRsLQKCKPCLDCSLLNR 100
Cdd:cd13421     8 LMCSASAEYSNCGENEYYNQTtGLCQQCPPCRPGEEPYMSCGYGTkDEDYGCVPCPAEKFSKGG-YQICRRHKDCEGFFR 86

                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*
gi 1207117557 101 FQKGNCSTT-NNAVCGDCLPGFY-RKTKLRGFQDMECIPCGDPPP 143
Cdd:cd13421    87 ATVLTPGDMeNDAECGPCLPGYYmLENRPRNIYGMVCYSCLLAPP 131

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as CD134 or OXO40; TNFRSF4 (also known as OX40, ACT35, CD134, IMD16, TXGP1L) activates NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. It also promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. It is primarily expressed on activated CD4+ and CD8+ T cells, where it is transiently expressed and upregulated on the most recently antigen-activated T cells within inflammatory lesions. This makes it an attractive target to modulate immune responses, i.e. TNFRSF4 (OX40) blocking agents to inhibit adverse inflammation or agonists to enhance immune responses. An artificially created biologic fusion protein, OX40-immunoglobulin (OX40-Ig), prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Some single nucleotide polymorphisms (SNPs) of its natural ligand OX40 ligand (OX40L, CD252), which is also found on activated T cells, have been associated with systemic lupus erythematosus.

                          10        20        30        40        50        60        70
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|...
gi 1207117557  49 CRQCDAGQELSKECGfgYGEDAQCVPCRASRFKEDRSLQKCKPCLDCSLLN-RFQKGNCSTTNNAVCGdCLPG 120
Cdd:cd13406    15 CHECPPGEGMESRCT--GTQDTVCSPCEPGFYNEAVNYEPCKPCTQCNQRSgSEEKQKCTKTSDTVCR-CRPG 84

Tumor necrosis factor receptor superfamily member 16 (TNFRSF16), also known as p75 neurotrophin receptor (p75NTR) or CD271; TNFRSF16 (also known as nerve growth factor receptor (NGFR) or p75 neurotrophin receptor (p75NTR or p75(NTR)), CD271, Gp80-LNGFR) is a common receptor for both neurotrophins and proneurotrophins, and plays a diverse role in many tissues, including the nervous system. It has been shown to be expressed in various types of stem cells and has been used to prospectively isolate stem cells with different degrees of potency. p75NTR owes its signaling to the recruitment of intracellular binding proteins, leading to the activation of different signaling pathways. It binds nerve growth factor (NGF) and the complex can initiate a signaling cascade which has been associated with both neuronal apoptosis and neuronal survival of discrete populations of neurons, depending on the presence or absence of intracellular signaling molecules downstream of p75NTR (e.g. NF-kB, JNK, or p75NTR intracellular death domain). p75NTR can also bind NGF in concert with the neurotrophic tyrosine kinase receptor type 1 (TrkA) protein where it is thought to modulate the formation of the high-affinity neurotrophin binding complex. On melanoma cell, p75NTR is an immunosuppressive factor, induced by interferon (IFN)-gamma, and mediates down-regulation of melanoma antigens. It can interact with the aggregated form of amyloid beta (Abeta) peptides, and plays an important role in etiopathogenesis of Alzheimer's disease by influencing protein tau hyper-phosphorylation. p75(NTR) is involved in the formation and progression of retina diseases; its expression is induced in retinal pigment epithelium (RPE) cells and its knockdown rescues RPE cell proliferation activity and inhibits RPE apoptosis induced by hypoxia. It can therefore be a potential therapeutic target for RPE hypoxia or oxidative stress diseases.

                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1207117557  44 GSCipCRQCDAGQELSKECGfgyGEDAQCVPCRASR-FKEDRS-LQKCKPCLDCSLLNRFqKGNCSTTNNAVCgDCLPGF 121
Cdd:cd13416    12 GEC--CEQCPPGEGVARPCG---DNQTVCEPCLDGVtFSDVVShTEPCQPCTRCPGLMSM-RAPCTATHDTVC-ECAYGY 84

                  ..
gi 1207117557 122 YR 123
Cdd:cd13416    85 YL 86

Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) in teleost; also known as TNFR2; This subfamily of TNFRSF1B (also known as TNFR2, type 2 TNFR, TNFBR, TNFR80, TNF-R75, TNF-R-II, p75, CD120b) is found in teleosts. It binds TNF-alpha, but lacks the death domain (DD) that is associated with the cytoplasmic domain of TNFRSF1A (TNFR1). It is inducible and expressed exclusively by oligodendrocytes, astrocytes, T cells, thymocytes, myocytes, endothelial cells, and in human mesenchymal stem cells. TNFRSF1B protects oligodendrocyte progenitor cells (OLGs) against oxidative stress, and induces the up-regulation of cell survival genes. While pro-inflammatory and pathogen-clearing activities of TNF are mediated mainly through activation of TNFRSF1A, a strong activator of NF-kappaB, TNFRSF1B is more responsible for suppression of inflammation. Although the affinities of both receptors for soluble TNF are similar, TNFRSF1B is sometimes more abundantly expressed and thought to associate with TNF, thereby increasing its concentration near TNFRSF1A receptors, and making TNF available to activate TNFRSF1A (a ligand-passing mechanism). Knockout studies in zebrafish embryos have shown that a signaling balance between TNFRSF1A and TNFRSF1B is required for endothelial cell integrity. TNFRSF1A signals apoptosis through caspase-8, whereas TNFRSF1B signals survival via NF-kB in endothelial cells. In goldfish (Carassius aurutus L.), TNFRSF1B expression is substantially higher than that of TNFRSF1 in tissues and various immune cell types. Both receptors are most robustly expressed in monocytes; mRNA levels of TNFRSF1B are lowest in peripheral blood leukocytes.

                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1207117557  38 EYKDKfGSCIPCRQCDAGQELSKECGfgYGEDAQCVPCRASRFKEDRS-LQKCKPCLDCSLLNRFQKG-NCSTTNNAVCG 115
Cdd:cd15835    11 EYYND-GSNLCCSKCRPGTRLKTKCS--ETSDTVCEPCPSGQYSENWNyYPNCFSCPKCKERKGLQYAqNCSSTTNAVCV 87

                          90       100
                  ....*....|....*....|....
gi 1207117557 116 dCLPGFYrktKLRGFQDMECIPCG 139
Cdd:cd15835    88 -CKPGMY---CIMGFDHPSCSECK 107